A peptide-based adjuvant therapy to reduce the toxicity of Amphotericin B

Project Member(s): Deplazes, E.

Funding or Partner Organisation: Gilead Sciences Inc. (Gilead Sciences Research Scholars Program)
Gilead Sciences Inc. (Gilead Sciences Research Scholars Program)

Start year: 2021

Summary: Amphotericin B (AMB) remains one of the most effective treatment for invasive fungal infections. However, the drug’s toxicity causes severe side effect and is a major dose-limiting factor. This project aims to elucidate the lipid-dependent mechanism of a peptide that is highly synergistic with AMB. The projected results have the potential to enable the development of adjuvant therapies that will reduce the toxicity of AMB.

FOR Codes: Proteins and peptides, Characterisation of biological macromolecules, Structural biology (incl. macromolecular modelling), Expanding Knowledge in the Biological Sciences, Expanding Knowledge in the Chemical Sciences

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.